143 related articles for article (PubMed ID: 38835915)
1. Clinical relevance and translational impact of reduced penetrance in genetic movement disorders.
Heinzel S; Mascalzoni D; Bäumer T; Berg D; Kasten M; Brüggemann N
Med Genet; 2022 Jun; 34(2):151-156. PubMed ID: 38835915
[TBL] [Abstract][Full Text] [Related]
2. Incomplete Penetrance and Variable Expressivity: From Clinical Studies to Population Cohorts.
Kingdom R; Wright CF
Front Genet; 2022; 13():920390. PubMed ID: 35983412
[TBL] [Abstract][Full Text] [Related]
3. Polygenic risk affects the penetrance of monogenic kidney disease.
Khan A; Shang N; Nestor JG; Weng C; Hripcsak G; Harris PC; Gharavi AG; Kiryluk K
medRxiv; 2023 May; ():. PubMed ID: 37214819
[TBL] [Abstract][Full Text] [Related]
4. Assessing the Pathogenicity, Penetrance, and Expressivity of Putative Disease-Causing Variants in a Population Setting.
Wright CF; West B; Tuke M; Jones SE; Patel K; Laver TW; Beaumont RN; Tyrrell J; Wood AR; Frayling TM; Hattersley AT; Weedon MN
Am J Hum Genet; 2019 Feb; 104(2):275-286. PubMed ID: 30665703
[TBL] [Abstract][Full Text] [Related]
5. LIPAD (LRRK2/Luebeck International Parkinson's Disease) Study Protocol: Deep Phenotyping of an International Genetic Cohort.
Usnich T; Vollstedt EJ; Schell N; Skrahina V; Bogdanovic X; Gaber H; Förster TM; Heuer A; Koleva-Alazeh N; Csoti I; Basak AN; Ertan S; Genc G; Bauer P; Lohmann K; Grünewald A; Schymanski EL; Trinh J; Schaake S; Berg D; Gruber D; Isaacson SH; Kühn AA; Mollenhauer B; Pedrosa DJ; Reetz K; Sammler EM; Valente EM; Valzania F; Volkmann J; Zittel S; Brüggemann N; Kasten M; Rolfs A; Klein C;
Front Neurol; 2021; 12():710572. PubMed ID: 34475849
[No Abstract] [Full Text] [Related]
6. Reduced penetrance of MODY-associated HNF1A/HNF4A variants but not GCK variants in clinically unselected cohorts.
Mirshahi UL; Colclough K; Wright CF; Wood AR; Beaumont RN; Tyrrell J; Laver TW; Stahl R; Golden A; Goehringer JM; ; Frayling TF; Hattersley AT; Carey DJ; Weedon MN; Patel KA
Am J Hum Genet; 2022 Nov; 109(11):2018-2028. PubMed ID: 36257325
[TBL] [Abstract][Full Text] [Related]
7. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
Simuni T; Uribe L; Cho HR; Caspell-Garcia C; Coffey CS; Siderowf A; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Tosun D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten SJ; Bressman S; Marek K;
Lancet Neurol; 2020 Jan; 19(1):71-80. PubMed ID: 31678032
[TBL] [Abstract][Full Text] [Related]
8. Incomplete penetrance and variable expressivity in monogenic diabetes; a challenge but also an opportunity.
Li M; Popovic N; Wang Y; Chen C; Polychronakos C
Rev Endocr Metab Disord; 2023 Aug; 24(4):673-684. PubMed ID: 37165203
[TBL] [Abstract][Full Text] [Related]
9. Determinants of penetrance and variable expressivity in monogenic metabolic conditions across 77,184 exomes.
Goodrich JK; Singer-Berk M; Son R; Sveden A; Wood J; England E; Cole JB; Weisburd B; Watts N; Caulkins L; Dornbos P; Koesterer R; Zappala Z; Zhang H; Maloney KA; Dahl A; Aguilar-Salinas CA; Atzmon G; Barajas-Olmos F; Barzilai N; Blangero J; Boerwinkle E; Bonnycastle LL; Bottinger E; Bowden DW; Centeno-Cruz F; Chambers JC; Chami N; Chan E; Chan J; Cheng CY; Cho YS; Contreras-Cubas C; Córdova E; Correa A; DeFronzo RA; Duggirala R; Dupuis J; Garay-Sevilla ME; García-Ortiz H; Gieger C; Glaser B; González-Villalpando C; Gonzalez ME; Grarup N; Groop L; Gross M; Haiman C; Han S; Hanis CL; Hansen T; Heard-Costa NL; Henderson BE; Hernandez JMM; Hwang MY; Islas-Andrade S; Jørgensen ME; Kang HM; Kim BJ; Kim YJ; Koistinen HA; Kooner JS; Kuusisto J; Kwak SH; Laakso M; Lange L; Lee JY; Lee J; Lehman DM; Linneberg A; Liu J; Loos RJF; Lyssenko V; Ma RCW; Martínez-Hernández A; Meigs JB; Meitinger T; Mendoza-Caamal E; Mohlke KL; Morris AD; Morrison AC; Ng MCY; Nilsson PM; O'Donnell CJ; Orozco L; Palmer CNA; Park KS; Post WS; Pedersen O; Preuss M; Psaty BM; Reiner AP; Revilla-Monsalve C; Rich SS; Rotter JI; Saleheen D; Schurmann C; Sim X; Sladek R; Small KS; So WY; Spector TD; Strauch K; Strom TM; Tai ES; Tam CHT; Teo YY; Thameem F; Tomlinson B; Tracy RP; Tuomi T; Tuomilehto J; Tusié-Luna T; van Dam RM; Vasan RS; Wilson JG; Witte DR; Wong TY; ; Burtt NP; Zaitlen N; McCarthy MI; Boehnke M; Pollin TI; Flannick J; Mercader JM; O'Donnell-Luria A; Baxter S; Florez JC; MacArthur DG; Udler MS
Nat Commun; 2021 Jun; 12(1):3505. PubMed ID: 34108472
[TBL] [Abstract][Full Text] [Related]
10. The Genetics of Parkinson's Disease and Implications for Clinical Practice.
Day JO; Mullin S
Genes (Basel); 2021 Jun; 12(7):. PubMed ID: 34208795
[TBL] [Abstract][Full Text] [Related]
11. LRRK2 in Parkinson's disease - drawing the curtain of penetrance: a commentary.
Krüger R
BMC Med; 2008 Nov; 6():33. PubMed ID: 18986509
[TBL] [Abstract][Full Text] [Related]
12. Leveraging genetic diversity to understand monogenic Parkinson's disease's landscape in AfrAbia.
Mohamed W
Am J Neurodegener Dis; 2023; 12(4):108-122. PubMed ID: 37736165
[TBL] [Abstract][Full Text] [Related]
13. Penetrance of Glucocerebrosidase (GBA) Mutations in Parkinson's Disease: A Kin Cohort Study.
Balestrino R; Tunesi S; Tesei S; Lopiano L; Zecchinelli AL; Goldwurm S
Mov Disord; 2020 Nov; 35(11):2111-2114. PubMed ID: 32767585
[TBL] [Abstract][Full Text] [Related]
14. Genetic modifiers of risk and age at onset in GBA associated Parkinson's disease and Lewy body dementia.
Blauwendraat C; Reed X; Krohn L; Heilbron K; Bandres-Ciga S; Tan M; Gibbs JR; Hernandez DG; Kumaran R; Langston R; Bonet-Ponce L; Alcalay RN; Hassin-Baer S; Greenbaum L; Iwaki H; Leonard HL; Grenn FP; Ruskey JA; Sabir M; Ahmed S; Makarious MB; Pihlstrøm L; Toft M; van Hilten JJ; Marinus J; Schulte C; Brockmann K; Sharma M; Siitonen A; Majamaa K; Eerola-Rautio J; Tienari PJ; ; Pantelyat A; Hillis AE; Dawson TM; Rosenthal LS; Albert MS; Resnick SM; Ferrucci L; Morris CM; Pletnikova O; Troncoso J; Grosset D; Lesage S; Corvol JC; Brice A; Noyce AJ; Masliah E; Wood N; Hardy J; Shulman LM; Jankovic J; Shulman JM; Heutink P; Gasser T; Cannon P; Scholz SW; Morris H; Cookson MR; Nalls MA; Gan-Or Z; Singleton AB
Brain; 2020 Jan; 143(1):234-248. PubMed ID: 31755958
[TBL] [Abstract][Full Text] [Related]
15. Polygenic risk alters the penetrance of monogenic kidney disease.
Khan A; Shang N; Nestor JG; Weng C; Hripcsak G; Harris PC; Gharavi AG; Kiryluk K
Nat Commun; 2023 Dec; 14(1):8318. PubMed ID: 38097619
[TBL] [Abstract][Full Text] [Related]
16. Offering preimplantation genetic testing for monogenic disorders (PGT-M) for conditions with reduced penetrance or variants of uncertain significance: Ethical insight from U.S. laboratory genetic counselors.
Porto A; Gaber Caffrey R; Crowley-Matoka M; Spencer S; Li M; Propst L
J Genet Couns; 2022 Feb; 31(1):261-268. PubMed ID: 34347921
[TBL] [Abstract][Full Text] [Related]
17. Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease.
Lai D; Alipanahi B; Fontanillas P; Schwantes-An TH; Aasly J; Alcalay RN; Beecham GW; Berg D; Bressman S; Brice A; Brockman K; Clark L; Cookson M; Das S; Van Deerlin V; Follett J; Farrer MJ; Trinh J; Gasser T; Goldwurm S; Gustavsson E; Klein C; Lang AE; Langston JW; Latourelle J; Lynch T; Marder K; Marras C; Martin ER; McLean CY; Mejia-Santana H; Molho E; Myers RH; Nuytemans K; Ozelius L; Payami H; Raymond D; Rogaeva E; Rogers MP; Ross OA; Samii A; Saunders-Pullman R; Schüle B; Schulte C; Scott WK; Tanner C; Tolosa E; Tomkins JE; Vilas D; Trojanowski JQ; ; Uitti R; Vance JM; Visanji NP; Wszolek ZK; Zabetian CP; Mirelman A; Giladi N; Orr Urtreger A; Cannon P; Fiske B; Foroud T
Ann Neurol; 2021 Jul; 90(1):76-88. PubMed ID: 33938021
[TBL] [Abstract][Full Text] [Related]
18. Environmental and Genetic Variables Influencing Mitochondrial Health and Parkinson's Disease Penetrance.
Zanon A; Pramstaller PP; Hicks AA; Pichler I
Parkinsons Dis; 2018; 2018():8684906. PubMed ID: 29707191
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic yield of multigene panel testing in an Israeli cohort: enrichment of low-penetrance variants.
Bernstein-Molho R; Friedman E; Kedar I; Laitman Y; Allweis TM; Gal-Yam EN; Feldman HB; Grinshpun A; Halpern N; Hartmajer S; Kadouri L; Katz LH; Kaufman B; Laish I; Levanon K; Philipsborn SL; Ludman M; Moran G; Peretz T; Reinstein E; Levi GR; Safra T; Shkedi S; Vinkler C; Levy Z; Goldberg Y
Breast Cancer Res Treat; 2020 Jun; 181(2):445-453. PubMed ID: 32303989
[TBL] [Abstract][Full Text] [Related]
20. Penetrance and expressivity of mitochondrial variants in a large clinically unselected population.
Cannon SJ; Hall T; Hawkes G; Colclough K; Boggan RM; Wright CF; Pickett SJ; Hattersley AT; Weedon MN; Patel KA
Hum Mol Genet; 2024 Feb; 33(5):465-474. PubMed ID: 37988592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
